Topotecan single-agent (platinum-resistant recurrent ovarian)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Components | DRUG-TOPOTECAN |
|---|
| ID | REG-TOPOTECAN-OVARIAN |
|---|---|
| Type | Regimen |
| Status | reviewed 2026-04-27 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-ESMO-OVARIAN-2024 SRC-NCCN-OVARIAN-2025 |
Notes
Weekly schedule (4 mg/m² days 1, 8, 15 q28d) preferred over historical ten Bokkel Huinink 5-day q21d schedule (1.5 mg/m² daily × 5) — similar ORR (~7-15% in platinum-resistant) with markedly less myelosuppression. ORR modest, response duration short, but useful when other options exhausted. Was control arm in MIRASOL alongside paclitaxel and PLD.
Used By
Indication
IND-OVARIAN-2L-PLAT-RES-TOPOTECAN- IND-OVARIAN-2L-PLAT-RES-TOPOTECAN